... WhatsApp

Study Finds No Added Benefit With Pembrolizumab in Advanced Prostate Cancer

You are here >> Home > Latest Updates > Prostate Cancer > Study Finds…

Study Finds No Added Benefit With Pembrolizumab in Advanced Prostate Cancer

For men with advanced prostate cancer that no longer responds to hormone therapy, new treatments are always being tested. One study looked at whether adding the immune therapy drug pembrolizumab to the standard treatment enzalutamide could help.

This large study included more than 1,200 men with metastatic castration-resistant prostate cancer (mCRPC). These men had not yet received chemotherapy for their advanced cancer. Half got pembrolizumab with enzalutamide, and half got enzalutamide with a placebo.

After over two years of follow-up, the results showed no improvement in survival. The group that got pembrolizumab did not live longer or stay free of cancer growth any longer than the group that did not. In fact, survival was slightly lower with pembrolizumab.

More side effects were also seen in the pembrolizumab group. About 31% had serious treatment-related problems, compared to only 11% in the placebo group. This led to more people stopping the treatment early.

Because of these results, the study was stopped early. The findings show that adding pembrolizumab to enzalutamide does not help men live longer and can cause more harm.

Rate this post

Exclusive Health Tips and Updates

dr swati shah - uro & gynec cancer surgeon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.